Keywords: topotarget, in-licenses, zemab, novartis, copenhagen, denmark-based, executed
TopoTarget in-licenses Zemab from Novartis
Article | 19 March 2007
Copenhagen, Denmark-based TopoTarget AS has executed its in-licensing option from Swiss drug major Novartis for the development and marketing of ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
